Compare BHV & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHV | MRKR |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 19.5M |
| IPO Year | 2002 | 2010 |
| Metric | BHV | MRKR |
|---|---|---|
| Price | $11.25 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | 6.5K | ★ 64.1K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.04 | $0.84 |
| 52 Week High | $15.15 | $2.46 |
| Indicator | BHV | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 37.42 |
| Support Level | $10.53 | $1.08 |
| Resistance Level | $12.99 | $1.31 |
| Average True Range (ATR) | 0.82 | 0.07 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 25.81 | 4.17 |
Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).